July 29, 2016 11:21 AM EDT

Protocols: BU’s Outterson helms $350M antibiotics project; Adaptimmune lands on EMA’s inside track

John Carroll

Editor & Founder

Kevin Outterson of Boston University’s School of Law has been tapped to run the new CARB-X program, a $350 million, public/private project that will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Protocols: BU’s Outterson helms $350M antibiotics project; Adaptimmune lands on EMA’s inside track

John Carroll

Editor & Founder

Sign up to read this article for free.

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Agenus launches biologics manufacturing business to generate cash

Pro­to­cols: BU’s Out­ter­son helms $350M an­tibi­otics project; Adap­ti­m­mune lands on EMA’s in­side track

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

Protocols: BU’s Outterson helms $350M antibiotics project; Adaptimmune lands on EMA’s inside track

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Agenus launches biologics manufacturing business to generate cash